TACC3 and glioma: Relevant information is provided by a study conducted by Singh et al. [149], which demonstrated that oral administration of AZD4547 resulted in prolonged survival of a FGFR3-TACC3-transformed glioma xenograft model compared with mice treated with the vehicle control [149].